Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis

References

• World Health Organization. Global Hepatitis Report 2017. World Health Organization; 2017.
   Google Scholar
• World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. World Health Organization; 2016.
   Google Scholar
• Chi H, Li Z, Hansen BE, et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol. 2019;17(1):182–191.
   PubMed Web of Science ®Google Scholar
• Ridruejo E, Marciano S, Galdame O, et al. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naive patients in clinical practice. Ann Hepatol. 2014;13(3):327–336.
   PubMed Web of Science ®Google Scholar
• Ye X-G, Su Q-M. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19(39):6665–6678.
   PubMed Web of Science ®Google Scholar
• Sims KA, Woodland AM. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. Pharmacotherapy. 2006;26(12):1745–1757.
   PubMed Web of Science ®Google Scholar
• Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009;3(3):425–433.
   PubMed Web of Science ®Google Scholar
• Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life -the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015;22(1):92.
   PubMedGoogle Scholar
• Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283. .
   PubMed Web of Science ®Google Scholar
• Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62(8):857–864.
   PubMed Web of Science ®Google Scholar
• Szabo SM, Hedegaard M, Chan K, et al. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Curr Med Res Opin. 2015;31(11):2031–2042.
   PubMed Web of Science ®Google Scholar
• Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ (Clin Res Ed). 2015;351:h4052.
   PubMedGoogle Scholar
• Katsanos K, Spiliopoulos S, Saha P, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. Plos One. 2015;10(8):e0135692.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–1315.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124.
   PubMed Web of Science ®Google Scholar
• Desantis SM, Zhu H. A bayesian mixed treatment comparisons meta-analysis of treatments for alcohol dependence and implications for planning future trials. Med Decis Making. 2014;34(7):899–910.
   PubMed Web of Science ®Google Scholar
• Chambers JD, Winn A, Zhong Y, et al. Potential role of network meta-analysis in value-based insurance design. Am J Manag Care. 2014;20(8):641–648.
   PubMed Web of Science ®Google Scholar
• Kanters S, Ford N, Druyts E, et al. Use of network meta-analysis in clinical guidelines. Bull World Health Organ. 2016;94(10):782–784.
   PubMed Web of Science ®Google Scholar
• Nikolakopoulou A, Mavridis D, Egger M, et al. Continuously updated network meta-analysis and statistical monitoring for timely decision-making. Stat Methods Med Res. 2018;27(5):1312–1330.
   PubMed Web of Science ®Google Scholar
• Zafar Z, Kristian T,J, Mark F, et al. Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes. Pharmacoeconomics. 2014;32(10):995–1004.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 162(11): 777–784. 2015.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on indirect treatment comparisons good research practices: part 1. Value Health. 14(4): 417–428. 2011.
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 14(4): 429–437. 2011.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2019 [cited 2019 Mar 20]. Available from https://training.cochrane.org/handbook/current
   Google Scholar
• Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
   PubMed Web of Science ®Google Scholar
• Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–406.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101(474):447–459.
   Web of Science ®Google Scholar
• van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285–299.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):956–964.
   PubMed Web of Science ®Google Scholar
• Toft N, Innocent GT, Gettinby G, et al. Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard. Prev Vet Med. 2007;79(2):244–256.
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
   PubMed Web of Science ®Google Scholar
• White IR, Barrett JK, Dan J, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–816.
   PubMed Web of Science ®Google Scholar
• Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38(6):818–826.
   PubMed Web of Science ®Google Scholar
• Yao GB, Cui ZY, Wang BE, et al. Long-term efficacy of 4 years trial of lamivudine for chronic hepatitis B. Chin J New Drugs Clin Remedies. 2003;22(10):587–593.
   Google Scholar
• Peters MG, Hw HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91–101.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198–1209.
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–536.
   PubMed Web of Science ®Google Scholar
• Zeng MD, Mao YM, Yao GB, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China. Chin J Infect Dis. 2005;23(6):387–394.
   Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–1010.
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011–1120.
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–2049.
   PubMed Web of Science ®Google Scholar
• Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745–754.
   PubMed Web of Science ®Google Scholar
• Chan HL, Wang H, Niu J, et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–353.
   PubMed Web of Science ®Google Scholar
• Yao GB, Chen CW, Lu WL, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1(3):365–372.
   PubMed Web of Science ®Google Scholar
• Yao GB, Zhou XQ, Xu DZ, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int. 2007;1(3):373–381.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–2455.
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology. 2009;49(1):72–79. .
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–495.
   PubMed Web of Science ®Google Scholar
• Shindo M, Chayama K, Mochida S, et al. Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int. 2009;3(3):445–452.
   PubMed Web of Science ®Google Scholar
• Lin Q, Zhang D, Zhou Z, et al. Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients. Chin J Hepatol. 2010;18(5):338–341.
   PubMedGoogle Scholar
• Huang J, Chen XP, Chen XF, et al. Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients. Chin J Hepatol. 2011;19(3):178–181.
   PubMedGoogle Scholar
• Li D, Long YZ, Zhao B, et al. Clinical efficacy of entecavir in treatment of chronic hepatitis B. Chin J Infect Control. 2011;10(4):263–265.
   Google Scholar
• Pradeep Kumar S, Medhi S, Asim M, et al. Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. Indian J Med Res. 2011;133:50–56.
   PubMed Web of Science ®Google Scholar
• Safadi R, Xie Q, Chen Y, et al. Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine. Liver Int. 2011;31(5):667–675.
   PubMed Web of Science ®Google Scholar
• Heo J, Park JY, Lee HJ, et al. A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. Antivir Ther. 2012;17(8):1563–1570. .
   PubMed Web of Science ®Google Scholar
• Ma X, Chen X, Chen X, et al. Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients. Chin J Hepatol. 2012;20(2):98–102.
   PubMedGoogle Scholar
• Jia JD, Hou JL, Yin YK, et al. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol Int. 2014;8(1):72–82.
   PubMed Web of Science ®Google Scholar
• Hou JL, Gao ZL, Xie Q, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial. J Viral Hepat. 2015;22(2):85–93.
   PubMed Web of Science ®Google Scholar
• Su M, Shang ZQ, Liang LF, et al. Clinical study of adefovir compared with entecavir in the treatment of chronic hepatitis B. Chin J Clin Pharmacol. 2015;31(4):256–258.
   Google Scholar
• Ahn SH, Heo J, Park JY, et al. A 96‐week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol. 2016;31(4):865–871. .
   PubMed Web of Science ®Google Scholar
• Lin H. Clinical efficacy of tenofovir and entecavir in the treatment of patients with HBeAg-positive newly diagnosed chronic hepatitis B. Shandong Med J. 2016;56(33):92–94.
   Google Scholar
• Luo X, Chen X, Chen R, et al. Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a. Chin J Hepatol. 2016;24(4):241–245.
   PubMedGoogle Scholar
• Yang W, Wang X, Ding Y, et al. Antiviral curative effect in patients with HBeAg-positive chronic hepatitis B. Chin J Nosocomial. 2016;26(7):1548–1550.
   Google Scholar
• An J, Lim YS, Kim GA, et al. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. BMC Gastroenterol. 2017;17(1):15.
   PubMedGoogle Scholar
• Sriprayoon T, Mahidol C, Ungtrakul T, et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatol Res. 2017;47(3):e161–e168. .
   PubMed Web of Science ®Google Scholar
• Zhang DF, Li S, Lu W, et al. Clinical efficacy of tenofovir and entecavir in the treatment of chronic hepatitis B infection in patients naïve to nucleosides and their analogues therapy. Int J Clin Exp Med. 2017;10(8):12329–12335.
   Web of Science ®Google Scholar
• Koike K, Suyama K, Ito H, et al. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol Res. 2018;48(1):59–68. .
   PubMed Web of Science ®Google Scholar
• Xing T, Xu H, Cao L, et al. HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLoS One. 2017;12(1):e0169444.
   PubMed Web of Science ®Google Scholar
• Wong WWL, Pechivanoglou P, Wong J, et al. Antiviral treatment for treatment-naive chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019;8(1):207.
   PubMed Web of Science ®Google Scholar
• Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168–175.
   PubMed Web of Science ®Google Scholar
• Wang FY, Li B, Li Y, et al. Entecavir for patients with hepatitis B decompensated cirrhosis in China: a meta-analysis. Sci Rep. 2016;6:32722.
   PubMed Web of Science ®Google Scholar
• Shen Y, Jia Y, Zhou J, et al. Bayesian network meta-analysis for assessing adverse effects of anti-hepatitis B drugs. Clin Drug Investig. 2019;39(9):835–846. .
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):834–840.
   PubMed Web of Science ®Google Scholar
• Liver EAftSot. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Su T, Liu C. Combination therapy for chronic hepatitis B: current updates and perspectives. Gut Liver. 2017;11(5):590–603.
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Lucejko M. siRNA drug development against hepatitis B virus infection. Expert Opin Biol Ther. 2018;18(6):609–617.
   PubMed Web of Science ®Google Scholar
• Schinazi RF, Ehteshami M, Bassit L, et al. Towards HBV curative therapies. Liver Int. 2018;38(S1):102–114. .
   PubMedGoogle Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844.
   PubMed Web of Science ®Google Scholar